Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Cash & Equivalents (2016 - 2025)

Palisade Bio has reported Cash & Equivalents over the past 16 years, most recently at $132.4 million for Q4 2025.

  • Quarterly Cash & Equivalents rose 1256.13% to $132.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $132.4 million through Dec 2025, up 1256.13% year-over-year, with the annual reading at $132.4 million for FY2025, 1256.13% up from the prior year.
  • Cash & Equivalents was $132.4 million for Q4 2025 at Palisade Bio, up from $5.2 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $132.4 million in Q4 2025 and troughed at $615000.0 in Q1 2021.
  • The 5-year median for Cash & Equivalents is $11.3 million (2024), against an average of $16.2 million.
  • The largest YoY upside for Cash & Equivalents was 1778.03% in 2021 against a maximum downside of 93.87% in 2021.
  • A 5-year view of Cash & Equivalents shows it stood at $10.5 million in 2021, then grew by 17.99% to $12.4 million in 2022, then grew by 0.4% to $12.4 million in 2023, then fell by 21.47% to $9.8 million in 2024, then skyrocketed by 1256.13% to $132.4 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Cash & Equivalents are $132.4 million (Q4 2025), $5.2 million (Q3 2025), and $5.4 million (Q2 2025).